# ABC123 (NCT03203369)

> Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

No report yet. It can be ordered.

- Drugs tested: UCART123
- Indication: blastic plasmacytoid dendritic cell neoplasm

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03203369
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Cellectis S.A.
- Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Interventions: UCART123
- Enrollment: 1
- Primary outcome: Incidence, nature, and severity of adverse events and serious adverse events

## Indexed commentary on ABC123 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=abc123-nct03203369